AMA approves CPT code for Axxent electronic brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

AMA approves CPT code for Axxent electronic brachytherapy

FREMONT, California—Xoft, Inc., maker of the FDA-approved Axxent Electronic Brachytherapy System (see Oncology NEWS International, June 2007, page 34) has announced that Axxent treatment now has a CPT reimbursement code. The American Medical Association CPT Editorial Panel approved the code (Category III CPT Code 0182T) for this novel form of high-dose-rate radiation therapy for the treatment of early-stage breast cancer. The code has been assigned a New Technology Ambulatory Payment Classification (APC), which secures payment for Medicare recipients who receive the treatment in the hospital outpatient setting.

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content